Formulation of immediate release of 4 - methyl - 3 - [[4 - (3-pyridinyl) - 2 - pirimidinil] amino] - N - [5 - (4 - methyl - 1H imidazol-1-yl) - 3 - (trifluoromethyl) phenyl]

发明人:: 1. BHARDWAJ, UPKAR,2. BORDAWEKAR, MANGESH SADASHIV,3. COMFORT, ANN REESE,4. LI, PING,5. LI, SHOUFENG,6. MAKAROV, ALEXEY

摘要：: A solid-state dosage form of nilotinib has been reported to include: (I) 4-methyl-3 - [[4 - (3-pyridyl-2-pyridyl] - amine] - N - [5 - (4-methyl-1h-pyridyl-1-il) - 3 - (trifluoromethyl) - phenyl] - zamida, or an acceptable pharmaceutical salt, and a precursor； and (II) in the case of less use of a powder material (only one). Silica, wherein the decomposition delay in the form of the curing dose.SE DA A CONOCER UNA FORMA DE DOSIFICACIÓN SÓLIDA DEL NILOTINIB QUE COMPRENDE: (I) UN NÚCLEO QUE COMPRENDE LA 4-METIL-3-[[4-(3-PIRIDINIL)-2-PIRIMIDINIL]-AMINO]-N-[5-(4-METIL-1H-IMIDAZOL-1-IL)-3-(TRIFLUORO-METIL)-FENIL]-BENZAMIDA, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA, Y EXCIPIENTES； Y (II) CUANDO MENOS UN POLÍMERO, RECUBRIENDO ESTE POLÍMERO AL NÚCLEO, EN DONDE SE DEMORA LA DESINTEGRACIÓN DE LA FORMA DE DOSIFICACIÓN SÓLIDA MENCIONADA.